Nolan Campbell

1.4k total citations
35 papers, 618 citations indexed

About

Nolan Campbell is a scholar working on Oncology, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Nolan Campbell has authored 35 papers receiving a total of 618 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 26 papers in Pathology and Forensic Medicine and 10 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Nolan Campbell's work include Polyomavirus and related diseases (27 papers), Multiple Sclerosis Research Studies (25 papers) and Acute Lymphoblastic Leukemia research (10 papers). Nolan Campbell is often cited by papers focused on Polyomavirus and related diseases (27 papers), Multiple Sclerosis Research Studies (25 papers) and Acute Lymphoblastic Leukemia research (10 papers). Nolan Campbell collaborates with scholars based in United States, Germany and Italy. Nolan Campbell's co-authors include Pei‐Ran Ho, Ih Chang, Sandra Richman, Harold Koendgen, Rachna Kasliwal, Stephanie Licata, Helmut Butzkueven, Ludwig Kappos, María Trojano and Heinz Wiendl and has published in prestigious journals such as Neurology, The Lancet Neurology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Nolan Campbell

32 papers receiving 610 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nolan Campbell United States 10 503 363 137 109 93 35 618
Mary Crossman United States 6 274 0.5× 342 0.9× 89 0.6× 87 0.8× 33 0.4× 8 522
Lana Zhovtis Ryerson United States 12 374 0.7× 181 0.5× 188 1.4× 86 0.8× 44 0.5× 36 509
Nora Möhn Germany 16 224 0.4× 306 0.8× 185 1.4× 127 1.2× 23 0.2× 49 699
Jai Perumal United States 14 385 0.8× 123 0.3× 184 1.3× 70 0.6× 45 0.5× 31 510
María Inmaculada Domínguez‐Mozo Spain 14 223 0.4× 139 0.4× 44 0.3× 129 1.2× 12 0.1× 40 575
Tuan Dong‐Si Germany 10 172 0.3× 182 0.5× 87 0.6× 50 0.5× 10 0.1× 14 517
Miguel Guerrero Spain 13 269 0.5× 151 0.4× 54 0.4× 193 1.8× 23 0.2× 17 481
Tarah Gustafson United States 6 210 0.4× 103 0.3× 86 0.6× 37 0.3× 14 0.2× 12 294
V. De Las Heras Spain 14 238 0.5× 134 0.4× 20 0.1× 220 2.0× 27 0.3× 21 508
S. Bamborschke Germany 11 107 0.2× 94 0.3× 83 0.6× 83 0.8× 11 0.1× 28 350

Countries citing papers authored by Nolan Campbell

Since Specialization
Citations

This map shows the geographic impact of Nolan Campbell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nolan Campbell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nolan Campbell more than expected).

Fields of papers citing papers by Nolan Campbell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nolan Campbell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nolan Campbell. The network helps show where Nolan Campbell may publish in the future.

Co-authorship network of co-authors of Nolan Campbell

This figure shows the co-authorship network connecting the top 25 collaborators of Nolan Campbell. A scholar is included among the top collaborators of Nolan Campbell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nolan Campbell. Nolan Campbell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hersh, Carrie M., Devon Conway, Elias S. Sotirchos, et al.. (2024). A 2-stage model of heterogenous treatment effects for brain atrophy in multiple sclerosis utilizing the MS PATHS research network. Multiple Sclerosis and Related Disorders. 91. 105847–105847.
2.
Scaramozza, Matthew, Patrizia A. Chiesa, Lauren Zajac, et al.. (2024). Konectom™ cognitive processing speed test enables reliable remote, unsupervised cognitive assessment in people with multiple sclerosis: Exploring the use of substitution time as a novel digital outcome measure. Multiple Sclerosis Journal. 30(9). 1193–1204. 4 indexed citations
3.
Butzkueven, Helmut, Tomáš Kalinčík, Francesco Patti, et al.. (2024). Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies. Therapeutic Advances in Neurological Disorders. 17. 4223502419–4223502419. 2 indexed citations
4.
Hersh, Carrie M., et al.. (2023). A 2-Stage Model of Heterogenous Treatment Effects for Brain Atrophy in MS Utilizing the MS PATHS Research Network (S27.001). Neurology. 100(17_supplement_2). 1 indexed citations
5.
Ryerson, Lana Zhovtis, Robert T. Naismith, Lauren Krupp, et al.. (2022). No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS. Multiple Sclerosis and Related Disorders. 58. 103480–103480. 12 indexed citations
6.
Foley, John, Carol M. Singh, Evan L. Riddle, et al.. (2022). Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice. Multiple Sclerosis Journal. 29(2). 196–205. 1 indexed citations
7.
Ryerson, Lana Zhovtis, Robert T. Naismith, Lauren Krupp, et al.. (2021). No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in MS PATHS (1964). Neurology. 96(15_supplement). 1 indexed citations
8.
Butzkueven, Helmut, Stephanie Licata, Douglas Jeffery, et al.. (2020). Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. BMJ Open. 10(10). e038861–e038861. 17 indexed citations
9.
10.
Butzkueven, Helmut, Ludwig Kappos, Heinz Wiendl, et al.. (2020). Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). Journal of Neurology Neurosurgery & Psychiatry. 91(6). 660–668. 99 indexed citations
11.
12.
Ryerson, Lana Zhovtis, John Foley, Ih Chang, et al.. (2019). Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 93(15). e1452–e1462. 116 indexed citations
13.
14.
15.
Berger, Thomas, Raju Kapoor, Hans‐Peter Hartung, et al.. (2019). Longitudinal stability of anti–JC virus (JCV) antibody index over 2 years in multiple sclerosis (MS) patients treated with natalizumab in the ASCEND study (P4.2-009). Neurology. 92(15_supplement). 2 indexed citations
16.
Ryerson, Lana Zhovtis, John Foley, Ih Chang, et al.. (2018). Natalizumab Extended Interval Dosing Is Associated with a Reduction in Progressive Multifocal Leukoencephalopathy (PML) Risk in the Touch® Registry. 10 indexed citations
17.
18.
Giovannoni, Gavin, Deborah Steiner, Finn Sellebjerg, et al.. (2017). Sustained Disability Improvement as Assessed by a Multicomponent Endpoint in Secondary Progressive Multiple Sclerosis (SPMS) Patients: A Post Hoc Analysis from ASCEND (P5.359). Neurology. 88(16_supplement). 3 indexed citations
19.
Licata, Stephanie, Helmut Butzkueven, Douglas Jeffery, et al.. (2017). Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study. Journal of the Neurological Sciences. 381. 246–246. 1 indexed citations
20.
Butzkueven, Helmut, Ludwig Kappos, María Trojano, et al.. (2016). Real-World Safety and Efficacy of Natalizumab after Switching from Other Disease-Modifying Therapies (DMTs): Data from the Tysabri® Observational Program (TOP) (P2.069). Neurology. 86(16_supplement). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary Crossman Breakdown of academic impact, for papers by Lana Zhovtis Ryerson Breakdown of academic impact, for papers by Nora Möhn Breakdown of academic impact, for papers by Jai Perumal Breakdown of academic impact, for papers by María Inmaculada Domínguez‐Mozo Breakdown of academic impact, for papers by Tuan Dong‐Si Breakdown of academic impact, for papers by Miguel Guerrero Breakdown of academic impact, for papers by Tarah Gustafson Breakdown of academic impact, for papers by V. De Las Heras Breakdown of academic impact, for papers by S. Bamborschke
Rankless by CCL
2026